Cumberland Pharmaceuticals (CPIX)
5.80
-0.04 (0.68%)
Upcoming Events
Latest Headlines
Cumberland reports positive cancer trial results for ifetroban drug
June 2, 2026 9:06 AM - StreetInsider
Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis
June 2, 2026 9:05 AM - PR NewsWire
RedHill explores opaganib for ebola outbreak response
June 2, 2026 8:00 AM - StreetInsider
RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms
June 2, 2026 8:00 AM - PR NewsWire
CUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV® IN CHINA
May 28, 2026 9:05 AM - PR NewsWire
Form DEFM14A CUMBERLAND PHARMACEUTICA
May 26, 2026 6:04 AM - SEC Filing
Form PREM14A CUMBERLAND PHARMACEUTICA For: May 15
May 15, 2026 4:33 PM - SEC Filing
Form 10-Q CUMBERLAND PHARMACEUTICA For: Mar 31
May 8, 2026 5:02 PM - SEC Filing
Cumberland Pharmaceuticals (CPIX) Reports Q1 Loss of $0.13
May 5, 2026 5:29 PM - StreetInsider
Form 8-K CUMBERLAND PHARMACEUTICA For: May 05
May 5, 2026 5:07 PM - SEC Filing
CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE
May 5, 2026 5:00 PM - PR NewsWire
RedHill's RHB-204 shows comparable efficacy to RHB-104 in lab tests
April 30, 2026 7:03 AM - StreetInsider
RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease
April 30, 2026 7:00 AM - PR NewsWire
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE
April 28, 2026 4:05 PM - PR NewsWire
RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights
April 27, 2026 8:00 AM - PR NewsWire
Form 8-K CUMBERLAND PHARMACEUTICA For: Apr 21
April 24, 2026 5:08 PM - SEC Filing
Form DEFA14A CUMBERLAND PHARMACEUTICA
April 23, 2026 9:03 AM - SEC Filing
Cumberland Pharmaceuticals to sell commercial unit to Apotex for $100 million
April 23, 2026 9:02 AM - StreetInsider
Form 8-K CUMBERLAND PHARMACEUTICA For: Apr 22
April 23, 2026 9:02 AM - SEC Filing
Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex
April 23, 2026 9:02 AM - PR NewsWire
RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026
April 22, 2026 8:01 AM - PR NewsWire
Cumberland Pharmaceuticals gets FDA approval for expanded Caldolor indication
April 16, 2026 9:06 AM - StreetInsider
CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR® (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITE
April 16, 2026 9:05 AM - PR NewsWire
Form 4 CUMBERLAND PHARMACEUTICA For: Mar 18 Filed by: Brown Martin S JR
March 20, 2026 5:24 PM - SEC Filing
Form 4 CUMBERLAND PHARMACEUTICA For: Mar 18 Filed by: Galante Joseph C
March 20, 2026 5:24 PM - SEC Filing
Form 4 CUMBERLAND PHARMACEUTICA For: Mar 18 Filed by: Jones James
March 20, 2026 5:23 PM - SEC Filing
Form 4 CUMBERLAND PHARMACEUTICA For: Mar 18 Filed by: Krogulski Kenneth
March 20, 2026 5:22 PM - SEC Filing
Form 4 CUMBERLAND PHARMACEUTICA For: Mar 18 Filed by: Young Caroline
March 20, 2026 5:22 PM - SEC Filing
Form 4 CUMBERLAND PHARMACEUTICA For: Mar 18 Filed by: Anthony Todd M.
March 20, 2026 5:21 PM - SEC Filing
Form 4 CUMBERLAND PHARMACEUTICA For: Mar 18 Filed by: Bitterman Chris T.
March 20, 2026 5:21 PM - SEC Filing
Form 4 CUMBERLAND PHARMACEUTICA For: Mar 18 Filed by: Hamm John M.
March 20, 2026 5:21 PM - SEC Filing
Form 4 CUMBERLAND PHARMACEUTICA For: Mar 18 Filed by: Herman James L
March 20, 2026 5:20 PM - SEC Filing
Form 4 CUMBERLAND PHARMACEUTICA For: Mar 18 Filed by: KAZIMI A J
March 20, 2026 5:20 PM - SEC Filing
Form 4 CUMBERLAND PHARMACEUTICA For: Mar 16 Filed by: KAZIMI A J
March 18, 2026 5:31 PM - SEC Filing
Cumberland Pharmaceuticals Launches New Sancuso® Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting
March 17, 2026 9:05 AM - PR NewsWire
Form ARS CUMBERLAND PHARMACEUTICA For: Mar 12
March 12, 2026 5:01 PM - SEC Filing
Form DEFA14A CUMBERLAND PHARMACEUTICA
March 9, 2026 5:04 PM - SEC Filing
Form DEF 14A CUMBERLAND PHARMACEUTICA For: Dec 31
March 9, 2026 5:02 PM - SEC Filing
Form 10-K CUMBERLAND PHARMACEUTICA For: Dec 31
March 9, 2026 6:03 AM - SEC Filing
Full Article List